Gain Therapeutics Inc. (GANX)
2.13
0.05 (2.40%)
At close: Jan 15, 2025, 3:59 PM
2.13
0.00%
After-hours Jan 15, 2025, 04:09 PM EST
undefined% (undefined)
| Bid | 2.13 |
| Market Cap | 56.50M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.07 |
| PE Ratio (ttm) | -1.99 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.5 |
| Volume | 86,407 |
| Avg. Volume (20D) | 284,729 |
| Open | 2.15 |
| Previous Close | 2.08 |
| Day's Range | 2.10 - 2.20 |
| 52-Week Range | 0.89 - 5.33 |
| Beta | undefined |
About GANX
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing s...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 19, 2021
Employees 29
Stock Exchange NASDAQ
Ticker Symbol GANX
Website https://www.gaintherapeutics.com
Analyst Forecast
According to 4 analyst ratings, the average rating for GANX stock is "Buy." The 12-month stock price forecast is $7.5, which is an increase of 252.11% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Gain Therapeutics Inc. is scheduled to release its earnings on Mar 25, 2025,
before market opens.
Analysts project revenue of $30.00K, reflecting a n/a YoY growth and earnings per share of -0.17, making a -41.38% decrease YoY.
Analysts project revenue of $30.00K, reflecting a n/a YoY growth and earnings per share of -0.17, making a -41.38% decrease YoY.
2 months ago ·
Source
+14.68%
Gain Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
3 months ago ·
Source
+17.03%
Gain Therapeutics shares are trading higher after the company announced the presentation of new evidence supporting the disease-modifying activity of Gt-02287 in preclinical animal models of both GBA-1 and idiopathic Parkinson's disease.
